{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:26:53Z","timestamp":1792794413089,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Agence Nationale de la Recherche sur le SIDA et les Maladies Infectieuses Emergentes","id":[{"id":"https:\/\/ror.org\/00rbzpz17","id-type":"ROR","asserted-by":"crossref"}]},{"name":"ANRS-MIE"},{"DOI":"10.13039\/100016726","name":"AVIRALIA Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016726","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This work aims to evaluate integrase resistance and its predictors in HIV-1 infected combined antiretroviral therapy (cART) experienced individuals failing a dolutegravir-based regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Major resistance mutations (MRM) and genotypic susceptibility score (GSS) of dolutegravir companion drugs were evaluated on plasma genotypic resistance test (GRT) performed at dolutegravir failure. Logistic regression was used to evaluate factors associated to the risk of integrase strand-transfer inhibitors (INSTI)-resistance at dolutegravir failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We retrospectively analysed 467 individuals. At failure GRT, individuals had been under dolutegravir for a median (IQR) time of 11 (5\u201320) months; around half of them had never been exposed to INSTI (52%) and 10.7% were at first-line regimen. Fifty-eight (12.4%) individuals showed \u22651 INSTI MRM. Among them, people INSTI-exposed showed significantly higher prevalence of INSTI resistance compared to those who were INSTI na\u00efve [46 (21.2%) versus 9 (3.9%), P\u200a&amp;lt;\u200a0.001].<\/jats:p>\n                    <jats:p>N155H was the most prevalent MRM (5.4%), followed by G140S (4.5%) and Q148H (4.3%). These MRM were more probably present in INSTI-experienced individuals compared to those INSTI na\u00efve. Despite failure, 89.5% of individuals harboured viral strains fully susceptible to dolutegravir and bictegravir and 85.0% to all INSTI. No INSTI exposure before receiving dolutegravir [OR: 0.35 (0.16\u20130.78), P\u200a&amp;lt;\u200a0.010] and a GSS for companion drugs \u22652 (OR: 0.09 [0.04\u20130.23], P\u200a&amp;lt;\u200a0.001) were negatively associated with INSTI resistance at failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a large set of individuals failing dolutegravir in real-life, INSTI resistance was low and mainly related to previous first-generation INSTI exposure. Surveillance of integrase resistance remains crucial to preserve efficacy of INSTI class in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkad101","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T19:13:37Z","timestamp":1679512417000},"page":"1415-1422","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings"],"prefix":"10.1093","volume":"78","author":[{"given":"Daniele","family":"Armenia","sequence":"first","affiliation":[{"name":"Saint Camillus International University of Health Sciences , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M","family":"Santoro","sequence":"additional","affiliation":[{"name":"University of Rome \u2018Tor Vergata\u2019 , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"Paris University, AP-HP, H\u00f4pital Bichat-Claude-Bernard, IAME , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Bertoli","sequence":"additional","affiliation":[{"name":"Polyclinic of Rome \u2018Tor Vergata\u2019 , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Forbici","sequence":"additional","affiliation":[{"name":"National Institute for Infectious Diseases L. Spallanzani, IRCCS , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, AP-HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, INSERM UMR-S1136 , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"Paris University, AP-HP, H\u00f4pital Bichat-Claude-Bernard, IAME , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[{"name":"University of Rome \u2018Tor Vergata\u2019 , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Genevieve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, AP-HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, INSERM UMR-S1136 , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-3522","authenticated-orcid":false,"given":"Philippe","family":"Flandre","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM UMR-S1136 , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"2023060100352615900_dkad101-B1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/phar.2246","article-title":"Integrase inhibitors: after 10 years of experience, is the best yet to come?","volume":"39","author":"Brooks","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2023060100352615900_dkad101-B2","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1517\/14656566.2015.1044436","article-title":"HIV integrase inhibitors: a new era in the treatment of HIV","volume":"16","author":"Blanco","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2023060100352615900_dkad101-B3","doi-asserted-by":"crossref","first-page":"106343","DOI":"10.1016\/j.ijantimicag.2021.106343","article-title":"HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance","volume":"57","author":"Mbhele","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2023060100352615900_dkad101-B4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1060028013513558","article-title":"Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection","volume":"48","author":"Rathbun","year":"2014","journal-title":"Ann Pharmacother"},{"key":"2023060100352615900_dkad101-B5","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1093\/jac\/dkab193","article-title":"Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey on behalf of the ANRS-MIE AC43 group","volume":"76","author":"Marcelin","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023060100352615900_dkad101-B6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijantimicag.2019.08.008","article-title":"Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors","volume":"54","author":"Yang","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023060100352615900_dkad101-B7","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/jac\/dkz021","article-title":"Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients","volume":"74","author":"Marcelin","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023060100352615900_dkad101-B8","first-page":"56","article-title":"Genetic barrier to resistance for dolutegravir","volume":"17","author":"Llibre","year":"2015","journal-title":"AIDS Rev"},{"key":"2023060100352615900_dkad101-B9","doi-asserted-by":"crossref","first-page":"104534","DOI":"10.1016\/j.jcv.2020.104534","article-title":"Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings","volume":"130","author":"Armenia","year":"2020","journal-title":"J Clin Virol"},{"key":"2023060100352615900_dkad101-B10","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/cid\/ciy1132","article-title":"Dolutegravir monotherapy versus dolutegravir\/abacavir\/lamivudine for virologically suppressed people living with chronic human immunodeficiency virus infection: the randomized noninferiority MONotherapy of TiviCAY trial","volume":"69","author":"Hocqueloux","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023060100352615900_dkad101-B11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2023060100352615900_dkad101-B12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"2023060100352615900_dkad101-B13","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/infdis\/jiy176","article-title":"HIV-1 resistance dynamics in patients with virologic failure to dolutegravir maintenance monotherapy","volume":"218","author":"Wijting","year":"2018","journal-title":"J Infect Dis"},{"key":"2023060100352615900_dkad101-B14","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/jac\/dkab448","article-title":"Specific mutations in the HIV-1 G-tract of the 3\u2019-polypurine tract cause resistance to integrase strand transfer inhibitors","volume":"77","author":"Hachiya","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023060100352615900_dkad101-B15","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00676-22","article-title":"Mutations in the 3\u2019-PPT lead to HIV-1 replication without integration","volume":"96","author":"Richetta","year":"2022","journal-title":"J Virol"},{"key":"2023060100352615900_dkad101-B16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/hiv.12692","article-title":"Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort","volume":"20","author":"Modica","year":"2019","journal-title":"HIV Med"},{"key":"2023060100352615900_dkad101-B17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1570162X20666220303104509","article-title":"Integrase strand transfer inhibitor (INSTI) genotypic resistance analysis in treatment-naive, INSTI free antiretroviral-experienced and INSTI-experienced Turkish patients infected with HIV-1","volume":"20","author":"Sayan","year":"2022","journal-title":"Curr HIV Res"},{"key":"2023060100352615900_dkad101-B18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/hiv.13062","article-title":"Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice","volume":"22","author":"Armenia","year":"2021","journal-title":"HIV Med"},{"key":"2023060100352615900_dkad101-B19","doi-asserted-by":"crossref","first-page":"ofaa202","DOI":"10.1093\/ofid\/ofaa202","article-title":"Emergent resistance to dolutegravir among INSTI-na\u00efve patients on first-line or second-line antiretroviral therapy: a review of published cases","volume":"7","author":"Cevik","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023060100352615900_dkad101-B20","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and safety of dolutegravir\u2013rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"key":"2023060100352615900_dkad101-B21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAI.0000000000002449","article-title":"Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials","volume":"85","author":"van Wyk","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023060100352615900_dkad101-B22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164753","article-title":"Switch to dolutegravir plus rilpivirine dual therapy in cART-experienced subjects: an observational cohort","volume":"11","author":"Capetti","year":"2016","journal-title":"PLoS One"},{"key":"2023060100352615900_dkad101-B23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/hiv.12506","article-title":"Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study","volume":"18","author":"Gantner","year":"2017","journal-title":"HIV Med"},{"key":"2023060100352615900_dkad101-B24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/hiv.13373","article-title":"Efficacy, durability, and tolerability of dolutegravir\/lamivudine and dolutegravir\/rilpivirine for the treatment of HIV in a real-world setting in Belgium","volume":"24","author":"Nasreddine","year":"2022","journal-title":"HIV Med"},{"key":"2023060100352615900_dkad101-B25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jac\/dkab367","article-title":"Dolutegravir-based dual maintenance regimens combined with lamivudine\/emtricitabine or rilpivirine: risk of virological failure in a real-life setting","volume":"77","author":"Deschanvres","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023060100352615900_dkad101-B26","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jgar.2022.01.018","article-title":"Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study","volume":"28","author":"Gagliardini","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2023060100352615900_dkad101-B27","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1089\/aid.2020.0261","article-title":"Integrase strand transfer inhibitor resistance in integrase strand transfer inhibitor-naive persons","volume":"37","author":"Bailey","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023060100352615900_dkad101-B28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance","volume":"75","author":"Tzou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023060100352615900_dkad101-B29","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance","volume":"74","author":"Rhee","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023060100352615900_dkad101-B30","doi-asserted-by":"crossref","first-page":"ofy329","DOI":"10.1093\/ofid\/ofy329","article-title":"Development of the R263K mutation to dolutegravir in an HIV-1 subtype D virus harboring 3 class-drug resistance","volume":"6","author":"Ahmed","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2023060100352615900_dkad101-B31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"Hiv drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"2023060100352615900_dkad101-B32","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"2023060100352615900_dkad101-B33","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1093\/jac\/dkab161","article-title":"Prevalence of genotypic baseline risk factors for cabotegravir\u200a+\u200arilpivirine failure among ARV-naive patients","volume":"76","author":"Charpentier","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023060100352615900_dkad101-B34","author":"European AIDS Clinical Society (EACS)","year":"2022"},{"key":"2023060100352615900_dkad101-B35","author":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2023060100352615900_dkad101-B36","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1128\/JVI.01535-07","article-title":"Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase","volume":"82","author":"Myers","year":"2008","journal-title":"J Virol"},{"key":"2023060100352615900_dkad101-B37","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/jac\/dks474","article-title":"HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes","volume":"68","author":"Reigadas","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2023060100352615900_dkad101-B38","doi-asserted-by":"crossref","first-page":"ofy221","DOI":"10.1093\/ofid\/ofy221","article-title":"Rapid development of high-level resistance to dolutegravir with emergence of T97A mutation in 2 treatment-experienced individuals with baseline partial sensitivity to dolutegravir","volume":"5","author":"George","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2023060100352615900_dkad101-B39","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/QAD.0000000000003288","article-title":"High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy","volume":"36","author":"Huik","year":"2022","journal-title":"AIDS"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/6\/1415\/50488920\/dkad101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/6\/1415\/50488920\/dkad101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T20:39:29Z","timestamp":1685565569000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/6\/1415\/7113317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,4,24]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad101","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,4,24]]}}}